褪黑素对急性冠脉综合征后患者抑郁症状、焦虑、昼夜节律及睡眠障碍的影响(MEDACIS):随机对照试验研究方案
MEDACIS是一项多中心、双盲、安慰剂对照随机临床试验,计划纳入240例无抑郁症状的急性冠脉综合征患者,分别接受25 mg褪黑素或安慰剂治疗12周,每2周用重性抑郁量表评估抑郁症状的发生与严重程度,以探究褪黑素对急性冠脉综合征后抑郁、焦虑、睡眠及昼夜节律紊乱的预防作用。
要点
- 急性冠脉综合征后约五分之一患者出现显著抑郁,焦虑和睡眠觉醒障碍也常见。
- MEDACIS纳入240例无抑郁症状的急性冠脉综合征患者,随机接受25 mg褪黑素或安慰剂治疗12周。
- 每2周用重性抑郁量表评估抑郁症状,以探究褪黑素的预防效果。
核心结论
- MEDACIS试验旨在探究预防性褪黑素治疗对急性冠脉综合征后抑郁、抑郁和焦虑症状、睡眠及昼夜节律紊乱是否具有预防作用。
研究设计与样本
- 多中心、双盲、安慰剂对照、随机临床试验,计划纳入240例急性冠脉综合征且无抑郁症状的患者。
- 患者随机接受25 mg褪黑素或安慰剂治疗,疗程12周。
- 每2周使用重性抑郁量表评估抑郁症状的发生与严重程度。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 干预剂量为25 mg褪黑素,疗程12周。
- 纳入标准为急性冠脉综合征且无抑郁症状,计划样本量240例。
- 每2周用重性抑郁量表评估抑郁症状。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression following acute coronary syndrome (ACS) constitutes a serious and debilitating problem. Approximately one in five patients will develop significant depression following ACS and less severe depressive symptoms are even more frequent. Furthermore, anxiety symptoms and sleep-wake disturbances are frequent. The objective of the MEDACIS trial is to investigate whether prophylactic treatment with melatonin has a preventive effect on depression, depressive and anxiety symptoms, sleep, and circadian disturbances following ACS. METHODS/DESIGN: "The effect of MElatonin and Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome" trial (MEDACIS) is a multicenter, double-blinded, placebo-controlled, randomized clinical trial. A total of 240 patients with ACS and no depressive symptoms will be included in the trial for treatment with either 25 mg melatonin or placebo for a 12-week period. Development and severity of depressive symptoms will be evaluated using Major Depression Inventory every 2 weeks with the purpose of investigating the potential preventive effect of melatonin on depressive symptoms. DISCUSSION: Previously, only selective serotonin reuptake inhibitors (SSRIs) have been investigated in a primary preventive setup in patients following ACS. However, SSRIs are associated with several side effects. An ideal intervention would constitute the highest degree of prevention of depressive symptoms with the lowest risk of side effects. In this regard, melatonin may have advantages due to its low toxicity as well as its proven anxiolytic and hypnotic effects. TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT02451293 . Registered on 12 May 2015. EudraCT nr. 2015-002116-32.
引用
- Madsen MT, Isbrand A, Andersen UO, et al. The effect of MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in patients after acute coronary syndrome (MEDACIS): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28228148. doi:10.1186/s13063-017-1806-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。